Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.

Andrew M BlumenfeldRamesh BoinpallyRosa De Abreu FerreiraJoel M TrugmanBrett DabruzzoJessica AilaniRichard B Lipton

Published in: Headache (2023)

The combination use of atogepant and ubrogepant was safe and well tolerated in adult participants with a history of migraine enrolled in the study. Pharmacokinetic changes during co-administration were not clinically meaningful.

Keyphrases

open label
emergency department
squamous cell carcinoma
radiation therapy
study protocol
phase ii study
adverse drug
drug induced